grocery glp-1 news Consumers Taking GLP-1s for Weight Loss, Current or Discontinued, Drive Lasting Changes in Retail, Per New Acosta Group Study 🥗📊 GLP-1 drugs are reshaping

He also reports being a consultant with Alnylam, AstraZeneca, Bayer, Horizon, Ionis, KBP Biosciences, Merck, Novo Nordisk, Quantum Genomics, and Vascular Dynamics

Nutrition Labels Deciphered: How to make smart choices based on nutrition information In een supermarkt vol overvloedige voedselkeuzes is het begrijpen van voedingsetiketten een echte sport geworden

From what weve seen so far, theres no problem there's no safety signal and there appears to be no contraindication at this time to using them, she says

Late 2024 to 2025 : After a GLP-1 NAION study was published potentially linking semaglutide GLP-1 medications to a higher risk of developing NAION, lawsuits and investigations began focusing on whether manufacturers failed to adequately warn about the risk of sudden vision loss, optic nerve damage, and permanent blindness

95 % 0,820,94

For the first primary endpoint, 62.9% of participants treated with semaglutide achieved resolution of steatohepatitis, with no worsening of liver fibrosis, compared to 34.1% on placebo (estimated difference in responder proportions [EDP] of 28.7%